Találati lista | Tudóstér

001-es BibID:	BIBFORM072422
Első szerző:	Feagan, Brian
Cím:	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease / Feagan B. G., Sandborn W. J., Gasink C., Jacobstein D., Lang Y., Friedman J. R., Blank M. A., Johanns J., Gao L. L., Miao Y., Adedokun O. J., Sands B. E., Hanauer S. B., Vermeire S., Targan S., Ghosh S., de Villiers W. J., Colombel J. F., Tulassay Z., Seidler U., Salzberg B. A., Desreumaux P., Lee S. D., Loftus E. V. Jr., Dieleman L. A., Katz S., Rutgeerts P., UNITI-IM-UNITI Study Group
Dátum:	2016
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban ustekinumab, Crohn's disease
Megjelenés:	The New England journal of medicine 375 : 20 (2016), p. 1946-1960. -
További szerzők:	Sandborn, William J. Gasink, C. Jacobstein, D. Lang, Y. Friedman, J. Blank, Marion Johanns, Jewel Gao, L. L. Miao, Y. Adedokun, Omoniyi J. Sands, Bruce E. Hanauer, Stephen B. Vermeire, S. Targan, Stephan Ghosh, Subrata de Villiers, W. J. Colombel, J. F. Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Seidler, U. Salzberg, B. A. Desreumaux, P. Lee, S. D. Loftus, Edward V. Dieleman, L. A. Katz, Seymour Rutgeerts, Paul Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) UNITI-IM-UNITI Study Group
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM028489
Első szerző:	Lakatos Péter (Semmelweis Egyetem)
Cím:	DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease / Lakatos P. L., Fischer S., Claes K., Kovacs A., Molnar T., Altorjay I., Demeter P., Tulassay Z., Palatka K., Papp M., Rutgeerts P., Szalay F., Papp J., Vermeire S., Lakatos L., The Hungarian IBD Study Group
Dátum:	2006
ISSN:	1078-0998
Megjegyzések:	Recent data suggest that haplotypic variants of the DLG5 gene on 10q23 are associated with susceptibility to inflammatory bowel disease (IBD) in Germany. In view of the geographical differences in frequency of genetic markers and the absence of data in Central European patients, our aim was to determine the DLG5 R30Q variant in Hungarian IBD patients. MATERIALS AND METHODS: We investigated 773 unrelated IBD patients (age 38.1 +/- 10.3 years; duration, 8.8 +/- 7.5 years; Crohn's disease [CD]: 639; male/female, 309/330; duration, 8.4 +/- 7.1 years; ulcerative colitis [UC]: 134; male/female, 63/71; duration, 10.6 +/- 8.9 years) and 150 healthy subjects. DLG5 R30Q and TLR4 D299G variants were tested by polymerase chain reaction/restriction fragment length polymorphism. DNA was screened for NOD2/CARD15 mutations by denaturing high-performance liquid chromatography. Detailed clinical phenotype was determined by reviewing the medical charts. RESULTS: The frequency of the R30Q variant allele was not significantly different in IBD (22.0%), CD (20.8%), and UC (27.6%) patients compared with healthy control subjects (28.0%). In CD, the 113A variant allele was associated with steroid resistance (16.3% vs noncarriers, 7.6%; odds ratio [OR], 2.4; 95% CI 1.3-4.5; P = 0.013). In a logistic regression model carriage of DLG5 R30Q, perianal involvement and frequent relapses were independently associated with steroid resistance. No phenotype-genotype associations were found in UC patients, although a trend toward more extensive disease was observed in carriers of the variant allele (OR = 2.1; 95% CI 0.95-4.4; P = 0.07). CONCLUSIONS: The present data strongly contrast previous data from Germany. DLG5 113A is not associated with disease susceptibility, but there was a tendency for this allele to confer resistance to steroids. Further studies are required to evaluate the significance of DLG5 in other populations from geographically diverse regions.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Inflammatory Bowel Diseases. - 12 : 5 (2006), p. 362-368. -
További szerzők:	Fischer Simon Claes, Karolien Kovács Ágota Molnár Tamás (orvos Szeged) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Demeter Pál Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Rutgeerts, Paul Szalay Ferenc (belgyógyász) Papp János (Budapest) Vermeire, S. Lakatos László (Veszprém) The Hungarian IBD Study Group
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM066565
Első szerző:	Regueiro, Miguel
Cím:	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection / Miguel Regueiro, Brian G. Feagan, Bin Zou, Jewel Johanns, Marion A. Blank, Marc Chevrier, Scott Plevy, John Popp, Freddy J. Cornillie, Milan Lukas, Silvio Danese, Paolo Gionchetti, Stephen B. Hanauer, Walter Reinisch, William J. Sandborn, Dario Sorrentino, Paul Rutgeerts, PREVENT Study Group
Dátum:	2016
ISSN:	0016-5085
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Gastroenterology 150 : 7 (2016), p. 1568-1578. -
További szerzők:	Feagan, Brian Zou, Bin Johanns, Jewel Blank, Marion Chevrier, Marc Plevy, Scott Popp, John Cornillie, Freddy J. Lukas, Milan Danese, Silvio Gionchetti, Paolo Hanauer, Stephen B. Reinisch, Walter Sandborn, William J. Sorrentino, Dario Rutgeerts, Paul Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) PREVENT Study Group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM036076
035-os BibID:	PMID:19637334
Első szerző:	Reinisch, Walter
Cím:	Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study / Walter Reinisch, Williem de Villiers, László Bene, László Simon, István Rácz, Seymour Katz, István Altorjay, Brian Feagan, Dennis Riff, Charles N. Bernstein, Daniel Hommes, Paul Rutgeerts, Antoine Cortot, Michael Gaspari, May Cheng, Tillman Pearce, Bruce E. Sands
Dátum:	2010
ISSN:	1078-0998
Megjegyzések:	BACKGROUND: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptoms. METHODS: A total of 201 patients with Crohn's Disease Activity Index (CDAI) scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 or 4.0 mg/kg fontolizumab or placebo, followed by up to 3 subcutaneous doses of 0.1 or 1.0 mg/kg fontolizumab or placebo every 4 weeks. Clinical response at day 29, the primary efficacy endpoint, was defined as a decrease in the CDAI of at least 100 points from baseline levels. RESULTS: Of 201 patients, 135 (67%) completed the study. Day 29 response rates were similar in all treatment groups (31%-38%). At subsequent timepoints a significantly greater proportion of patients in the 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous fontolizumab group had clinical response and significantly greater improvement in the CDAI score compared with patients who received placebo. All fontolizumab groups had significant improvement in C-reactive protein levels. The overall frequency of adverse events was similar in all groups (58%-75%); most events were related to exacerbation of CD. There was a low frequency (5.2%) of neutralizing antibodies to fontolizumab. CONCLUSIONS: Although a strong clinical response to fontolizumab was not observed, significant decreases in C-reactive protein levels suggest a biological effect. Fontolizumab was well tolerated, and further studies to assess its efficacy are warranted.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban külföldön készült közlemény
Megjelenés:	Inflammatory Bowel Diseases 16 : 2 (2010), p. 233-42. -
További szerzők:	Villiers, Williem de Bene László (Budapest) Simon László (orvos Szekszárd) Rácz István (orvos Győr) Katz, Seymour Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Feagan, Brian Riff, Dennis Bernstein, Charles N. Hommes, Daniel Rutgeerts, Paul Cortot, Antoine Gaspari, Michael Cheng, May Pearce, Tillman Sands, Bruce E.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: